How many studies have been conducted on Epoetin Alfa?

BiohacksAI has indexed 298 PubMed studies on Epoetin Alfa, including 93 randomized controlled trials (RCTs). 90% of studies involve human subjects.

What are the main research areas for Epoetin Alfa?

The primary research domains for Epoetin Alfa are 🔬 Oncology, 🫘 Kidney, 😴 Sleep. This is based on analysis of 298 PubMed studies using the BiohacksAI evidence platform.

BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.

Epoetin Alfa

A recombinant glycosylated form of erythropoietin which stimulates the differentiation and proliferation of erythroid precursors. It is used for the treatment of ANEMIA associated with CHRONIC RENAL FAILURE in dialysis and predialysis patients.

298+ PubMed studies analyzed · 93 RCTs · Evidence Score: 60.3

Research Domains

Epoetin Alfa has been studied across 10 research domains including 🔬 Oncology, 🫘 Kidney, 😴 Sleep, ⚡ Energy & Fatigue, ❤️ Cardiovascular. The primary research focus is 🔬 Oncology with 38% of studies addressing this area.

Loading evidence profile...

This evidence profile for Epoetin Alfa is generated deterministically from 298 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.